Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.

  • Zevra Therapeutics' Profit After Tax rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13941.6%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
  • Per Zevra Therapeutics' latest filing, its Profit After Tax stood at -$544000.0 for Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Profit After Tax peaked at $74.7 million during Q2 2025, and registered a low of -$35.7 million during Q4 2024.
  • Its 5-year average for Profit After Tax is -$5.6 million, with a median of -$10.3 million in 2021.
  • As far as peak fluctuations go, Zevra Therapeutics' Profit After Tax surged by 62211.87% in 2021, and later plummeted by 67438.79% in 2024.
  • Zevra Therapeutics' Profit After Tax (Quarter) stood at -$2.7 million in 2021, then skyrocketed by 312.73% to $5.8 million in 2022, then plummeted by 445.2% to -$19.8 million in 2023, then plummeted by 80.05% to -$35.7 million in 2024, then surged by 98.48% to -$544000.0 in 2025.
  • Its Profit After Tax stands at -$544000.0 for Q3 2025, versus $74.7 million for Q2 2025 and -$3.1 million for Q1 2025.